Accepted answer
The switch to a low-dead-space syringe nearly doubles your usable vial, which is better than switching suppliers if you are looking for cost savings.
The complete rule: fix the syringe architecture first, and then the reconstitution volume becomes a free choice you can make on stability grounds rather than on economics.
Dead space by syringe type
| Configuration | Dead volume | Loss at 5 mg/mL | Over 20 draws |
|---|
| Fixed-needle insulin syringe | 3–5 µL | 15–25 µg | 0.3–0.5 mg |
| Low-dead-space, detachable | <2 µL | <10 µg | <0.2 mg |
| Standard luer-lock + 30G | 35–60 µL | 175–300 µg | 3.5–6 mg |
| Luer-lock + 21G drawing needle | 70–100 µL | 350–500 µg | 7–10 mg |
Put another way, corollary that follows immediately: changing needle gauge or length barely changes your losses.
The World Health Organisation guidance on injection equipment adopted the same high-versus-low dead-space distinction, using a low-dead-space threshold in the low single-digit microlitres.
One qualification: the dead space does not affect the dose accuracy if the hub was full of solution at the start of the draw.
The switch nearly doubles your vial, which is better than most other optimisations combined.